Navigation Links
LaVoie Group Adds Bio-Surgery Company, Pegasus Biologics, to Its Life Sciences Agency Roster
Date:4/27/2009

SALEM, Mass., April 27 /PRNewswire/ -- LaVoie Group, a life science-focused strategic communications agency, announced today that it has been selected as investor relations agency of record for Pegasus Biologics, Inc.

Donna L. LaVoie, President & CEO of LaVoie Group, commented, "Pegasus has the opportunity to capture the significant market share in the bio-surgery area. The Company is changing the standard of care in three initial markets: limb preservation, orthopedics, and shortly in ventral hernia repair. The addition of Pegasus underscores the increasingly diverse nature of our life sciences roster."

Michael Will, Chief Executive Officer of Pegasus Biologics, commented, "LaVoie Group has the necessary experience, skills and relationships to help capture our corporate story and articulate it to our target investor audiences. Their perspective and creative approach is already proving invaluable as we work to communicate our value proposition."

About Pegasus Biologics

Pegasus Biologics, Inc. (Irvine, CA) is a commercialization-stage company with products expected to change the standard of care in the bio-surgery solution market. Additional information on the Company can be found at http://www.pegasusbio.com.

About LaVoie Group, Inc.

LaVoie Group provides senior-level strategic counsel and tactical implementation of venture, investor and public relations programs designed to properly position, create visibility and drive value for each client. We help our life sciences companies attract capital, reach corporate partners, generate revenue and build their companies through integrated communications programs. In addition to Pegasus, our clients range from privately held development stage companies to industry leaders in life sciences such as Vertex Pharmaceuticals, ESBATech AG, and Agile Therapeutics.

In March 2009, LaVoie Group was awarded the coveted 2008 Impact Award for "Best Industry-Exclusive Agency," sponsored by the League of American Communications Professionals (LACP). LaVoie Group is ranked by O'Dwyer's PR Report as one of the leading independent healthcare PR firms in the U.S. For more information, please visit http://www.lavoiegroup.com.


'/>"/>
SOURCE LaVoie Group
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Avicena Group to Present at Noble Financial Conference
2. Chrome Group to Seek Listing for Some of its Subsidiaries
3. Dr. Amit Dhawan Promoted to Medical Director for The Mattson Jack Group
4. Reed Group to Provide MDA Internet Disability Duration Guidelines to U.S. Navy
5. SportCoatings; The North American Booster Club Association (NABCA); the Coatings Specialist Group New Booster Program Goes High Tech With Invisible Antimicrobial Defense
6. Revolutionary Genomics Research Group Opens Boston Office; Provides DNA Evidence in Workers Comp Cases
7. Millennium Biotechnologies Group, Inc. (MBTG.OB) Announces Completion of $2,277,000 Equity Financing
8. ThirdBiotech Networking Group Launches
9. Millennium Biotechnologies Group, Inc. (MBTG.OB) Announces Appointment of Mark C. Mirken as its President and Chief Operating Officer
10. Reed Group Ltd. Announces Enterprise License for New Zealands Accident Compensation Corporation
11. Rosetta Genomics to Webcast Presentation at Maxim Group Growth Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... India , Jan. 19, 2017  Market Research Future has ... Global Market for Liquid Biopsy is growing rapidly and expected to ... Market Highlights ... The Global Liquid Biopsy Market has been assessed as a ... growth figures and boom in the coming future. There has been ...
(Date:1/19/2017)... , Jan 19, 2017 Research and Markets ... has announced the addition of ... Material, Application - Forecast to 2025" report to their ... The report provides a detailed analysis on current and ... forecasts till 2025, using estimated market values as the base numbers ...
(Date:1/19/2017)... and GAITHERSBURG, Md. , Jan. ... and Altimmune, Inc., a privately-held immunotherapeutics company targeting ... definitive agreement for the merger of PharmAthene and ... include Novartis Venture Fund, HealthCap, Truffle Capital and ... fully-integrated and diversified immunotherapeutics company with four clinical ...
(Date:1/19/2017)... ... January 18, 2017 , ... The ... (NIH) to update its Data Sharing Policy. Specifically, the nation’s leading informatics experts, ... subject to the existing policy. AMIA recommended that NIH earmark funding for researchers ...
Breaking Biology Technology:
(Date:1/18/2017)... , Jan. 18, 2017 ... company that supports the entire spectrum of clinical ... been another record-breaking year for the organization in ... interest in MedNet,s eClinical products and services. The ... tremendous marketplace success of iMedNet ...
(Date:1/12/2017)... NEW YORK , Jan. 12, 2017  New research ... around the office of the future.  1,000 participants were simply ... last three months which we may consider standard issue.  Insights ... office of 2017 were also gathered from futurists and industry ... and Dr. James Canton .  Some ...
(Date:1/11/2017)... NEW BRUNSWICK, N.J. , Jan. 11, 2017  Michael Johnson, ... from Foundation Venture Capital Group, Inc., has been named to the ... Johnson, 27,  was one of 600 people in 20 fields ... only four percent of the 15,000 applicants were selected. ... He is currently a PhD ...
Breaking Biology News(10 mins):